HER2 gene amplification and protein overexpression are identified in about 6% of CRC patients and may be successfully evaluated both by IHC and ISH with high concordance rates, giving these patients new treatment opportunities by making them potential candidates for anti-HER2 therapy [6,10,12,14,50]. Here, ERBB2 is linked to colorectal carcinoma.